BackAdma Biologics Overview

Adma Biologics Receivables

Latest receivables for ADMA: $140M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$138.23M
↑ 25.98% YoYΔ $28.50M vs prior year quarter

Peer trimmed avg / median

Loading

Adma Biologics Receivables History

Loading

Adma Biologics vs. peers: Receivables Comparison

Loading

Adma Biologics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Adma Biologics (ADMA) FAQ

As of the most recent data (June 2026), ADMA shows a receivables of $140M. That compares with $110M in the prior-year period — up 26.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADMA's receivables is now $140M (was $110M) — a 26.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Adma Biologics is outperforming or lagging.

Tracking ADMA's receivables over time shows whether Adma Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $140M That compares with $110M in the prior-year period — up 26.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Adma Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $140M) with ownership activity and broader fundamentals.

Adma Biologics's receivables is $140M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.